Emicizumab in Patients With Acquired Hemophilia A

Inclusion Criteria: * Signed Informed Consent/Assent Form * Age ≥18 years at time of signing Informed Consent Form * Ability to comply with the study protocol, in the investigator's judgment * Diagnosis of AHA based on a reduced FVIII activity (\<50 %) and positive FVIII inhibitor (\>0.6 BU/ml) at screening (local laboratory) * Current bleeding due to AHA at the time of screening * Plan to be adherent to emicizumab prophylaxis during the study * For women of childbearing potential who meet the following criteria: * Refrain from heterosexual intercourse or use contraceptive methods that result in a failure rate of \<1% per year during the study period A woman with ≥ 12 continuous months of amenorrhea with no identified cause other than menopause and has not undergone surgical sterilization (removal of ovaries and/or uterus). use of combined oral or injected hormonal contraceptive, bilateral tubal ligation, male sterilization, hormone- releasing intrauterine devices, and copper intrauterine devices. Exclusion Criteria: * Congenital hemophilia A * Treatment with aPCC within the last 24 hours before first study treatment or planned treatment with aPCC during the course of the study * Known positive lupus anticoagulant at the time of screening * Severe uncontrolled infection at the time of screening * Signs of active disseminated intravascular coagulation at the time of screening - * Emicizumab ⎯ AHA Emi Version 1.0 20 * Current treatment for thromboembolic disease or signs of …